to accelerate their platform which combines human immune organoid biology with generative AI to help antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.
ALP Bio AG has raised €2.1M across 2 funding rounds from 3 investors, most recently a round in Jul 2026. Based in Schlieren, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-07-03 | Other | €163k | Venture Kick | View deal → |
| 2026-04-30 | Pre-Seed | €1.9M | 42CAP,strategic angel investors,Venture Kick | View deal → |
